MPM BIOVENTURES 2018, L.P.

About MPM BIOVENTURES 2018, L.P.

MPM BIOVENTURES 2018, L.P. is an investment vehicle associated with MPM Capital and active in biotechnology financing across public and private markets. In the companies identified here, it appears as an institutional investor and/or significant shareholder connected to capital-raising and market activities, including Entrada Therapeutics, Inc. and iTeos Therapeutics, Inc. The publicly available information points to a role centered on growth financing and support for clinical-stage companies, rather than a traditional operating executive mandate. At iTeos, MPM participated in the company’s 2018 Series B financing, which was intended to accelerate development of the immuno-oncology pipeline and support expansion into the United States. At Entrada, MPM was also a co-investor in the company’s 2018 Series A financing, helping advance its intracellular biologics delivery platform. From a corporate governance perspective, this affiliation reflects expertise in capital allocation, strategic support for innovative life sciences businesses, and identifying value-creation opportunities in healthcare. The notable decisions associated with this entity are therefore primarily investment decisions: backing financings, structuring ownership positions, and supporting the development path of portfolio companies. Because public sources do not clearly identify a more specific individual executive role tied to this name, it is best to describe MPM BIOVENTURES 2018, L.P. conservatively as a specialized investment entity whose influence is exercised mainly through ownership, financing, and shareholder governance.